樂普生物-B：2023年度報告

Futu NewsApr 25 17:01 · Announcements

Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 7% to complete clinical trial of a drug to treat advanced solid tumors

Lepu Bio-B (02157) rose more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.

Zhitong FinanceApr 23 14:35

Hong Kong stock changes丨Lepu Biotech surged 13%, completed clinical trials of new drugs for the first time

Glonghui, April 15 | Lepu Bio-B (2157.HK) once again increased by more than 13%, rising more than 30% on the 6th. It now reports HK$4.33, hitting a new high of more than 3 months, with a market value of HK$7.2 billion. The company recently announced that Kym, a joint venture with Conoa-B, has signed a license agreement with AstraZeneca to develop and commercialize CMG901. Currently, AstraZeneca has carried out a number of clinical studies on CMG901 treatment for advanced solid tumors. Among them, one is an advanced or metastatic gastric and gastroesophageal junction gland that expresses Claudin 18.2

Gelonghui FinanceApr 15 11:30

Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901

Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).

Gelonghui FinanceApr 15 08:10

Lepu Bio-B (02157.HK) In-depth Research Report: ADC pipelines are rich in IO+ADC leading layout

Lepu Biotech is an innovative biopharmaceutical company focusing on the field of cancer treatment, especially targeted therapy and immunotherapy. The company is committed to developing innovative ADCs through an advanced ADC technology development platform, and has already listed PD-1 with the company

華創證券Apr 13 00:00

Changes in Hong Kong stocks 丨 Lepu Biotech surged more than 13%, and revenue surged 1347.2% in 2023

Glonghui, April 2 | Lepu Bio-B (2157.HK) rose intraday today, at one point rising by more than 13% to HK$3.61. According to the news, the company announced results on March 27, showing that revenue in 2023 increased from about RMB 16 million in the previous year to about RMB 225 million, an increase of about 1347.2%; the company's losses to its mother fell sharply by about 96.8%, from about RMB 689 million in the previous year to about RMB 122 million in the same year. According to reports, Lepu Bio-B achieved breakthrough revenue during the reporting period. Group BD revenue and subsequent technology

Gelonghui FinanceApr 2 10:32